Safety experience with caspofungin in pediatric patients.

Published

Journal Article

We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.

Full Text

Duke Authors

Cited Authors

  • Zaoutis, T; Lehrnbecher, T; Groll, AH; Steinbach, WJ; Jafri, HS; Maertens, J; Ngai, AL; Chow, JW; Taylor, AF; Strohmaier, KM; Bourque, M; Bradshaw, SK; Petrecz, M; Kartsonis, NA

Published Date

  • December 2009

Published In

Volume / Issue

  • 28 / 12

Start / End Page

  • 1132 - 1135

PubMed ID

  • 19779392

Pubmed Central ID

  • 19779392

Electronic International Standard Serial Number (EISSN)

  • 1532-0987

Digital Object Identifier (DOI)

  • 10.1097/INF.0b013e3181af5a15

Language

  • eng

Conference Location

  • United States